IDEXX Laboratories, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $1.06B | $887.9M | $845.0M | $679.1M | $744.8M | $581.8M | $427.7M | $377.0M |
| Depreciation & Amortization | $145.2M | $129.9M | $114.9M | $111.9M | $104.6M | $96.0M | $88.0M | $83.2M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | $20.2M | $17.1M | $13.8M | $15.0M | $12.1M | $9.8M | $9.4M | $8.9M |
| Stock-Based Compensation | $60.0M | $60.3M | $59.7M | $49.8M | $37.8M | $31.0M | $39.3M | $25.2M |
| Net Cash from Operating Activities | $1.18B | $929.0M | $906.5M | $543.0M | $755.5M | $648.1M | $459.2M | $400.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $124.7M | $120.9M | $133.6M | $148.8M | $119.5M | $107.0M | $155.0M | $115.8M |
| Business Acquisitions | $0 | $76.7M | $0 | $11.5M | $173.4M | $1.5M | $50.3M | $22.5M |
| Net Cash from Investing Activities | $-136.2M | $-207.1M | $-125.3M | $-195.4M | $-293.0M | $-109.4M | $-205.5M | $138.6M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $1.22B | $837.0M | $71.9M | $819.7M | $746.8M | $182.8M | $301.7M | $369.3M |
| Net Cash from Financing Activities | $-1.16B | $-878.1M | $-442.0M | $-370.9M | $-697.4M | $-248.4M | $-286.4M | $-597.8M |
| Net Change in Cash | $-108.2M | $-165.7M | $341.4M | $-31.9M | $-239.5M | $293.6M | $-33.5M | $-63.9M |
| Free Cash Flow | $1.06B | $808.1M | $772.9M | $394.1M | $636.0M | $541.1M | $304.2M | $284.3M |